215724-77-9

Upstream product

• 495-19-2 norarecoline 
• 63-75-2 arecoline 
• 215725-60-3 tert-butyl 5-(hydroxymethyl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 100-44-7 benzyl chloride 
• 169105-89-9 isofagomine 
• 319924-29-3 1,1-Dibromo-5-[(tert-butyldimethylsilyl)oxy]-1,2-dideoxy-3,4-O-(1-methylethylidene)-D-threo-pent-1-ene 
• 319924-32-8 1-[Benzyl(trimethylsilylmethyl)amino]-1,4,5-trideoxy-2,3-O-(1-methylethylidene)-D-threo-pent-4-ynitol 
• 319924-33-9 (3aR,7aR)-5-benzyl-2,2-dimethyl-7-methylenehexahydro-[1,3]dioxolo[4,5-c]pyridine 
• 319924-30-6 5-[(tert-Butyldimethylsilyl)oxy]-1,2-dideoxy-3,4-O-(1-methylethylidene)-D-threo-pent-1-yne 
• 319924-31-7 (4S,5R)-4-(Bromomethyl)-5-ethynyl-2,2-dimethyl-1,3-dioxolane 
• 320396-46-1 1,2-Dideoxy-3,4-O-(1-methylethylidene)-D-threo-pent-1-ynitol 
• 100-46-9 benzylamine 
• 53215-95-5 N-(trimethylsilylmethyl)benzylamine 
• 855298-05-4 (5R)-5-hydroxymethyl-7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylic acid tert-butyl ester 

Downstream Products

• 215725-53-4 (3R,4R,5R)-1-benzyl-3-(benzyloxy)-5-(hydroxymethyl)piperdin-4-ol 
• 169105-89-9 isofagomine 

Relevant academic research and scientific papers

METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS

The present invention provides methods for preventing and/or treating lysosomal storage disorders using 5-(fluoromethyl)piperidine-3,4-diol, 5-(chloromethyl)piperidine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.

A novel approach to both the enantiomers of potent glycosidase inhibitor isofagomine via PET-promoted cyclization of 1-[benzyl(trimethylsilylmethyl)amino]-1,4,5-trideoxy-2,3-O-(1- methylethylidene)-threo-pent-4-ynitol

The cyclization of PET-generated α-trimethylsilylmethylamine radical cation to a tethered acetylene moiety has been exploited to solve the problem of the generation of an aminomethyl group next to a stereocenter in the synthesis of 1-N-iminosugar type glycosidase inhibitors. Its success is demonstrated by the synthesis of (+)- as well as (-)-isofagomine, an extremely potent β-glucosidase inhibitor of the 1-N-iminosugar class.

Iminosugars: Potential inhibitors of liver glycogen phosphorylase

The first synthesis of the single isomers 3R, 4R, 5R); 3S,4S,5S); 3R,4R,5S) and 3S,4S, 5R) of 5-hydroxymethyl-piperidine-3,4-diol from Arecolin is reported, including the synthesis of a series of N-substituted derivatives of the 3R,4R,5R)-isomer Isofagomi

A general strategy towards the synthesis of 1-N-iminosugar type glycosidase inhibitors: Demonstration by the synthesis of D- as well as L-glucose type iminosugars (isofagomines)

Both enantiomers of isofagomine, the potent glycosidase inhibitor of a type 1-N-iminosugar have been synthesized by the intramolecular cyclization of the PET generated α-trimethylsilylmethylamine radical cation with the appropriate tethered acetylene moiety. (C) 2000 Published by Elsevier Science Ltd.

Heterocyclic compounds

Novel piperidine compounds are provided, and those compounds are useful in the treatment and/or prevention of diabetes, and especially non-insulin dependent diabetes (NIDDM or type 2 diabetes) including overnight or meal treatment and treatment or prevention of longterm complications, such as retinopathy, neuropathy, nephropathy, and micro- and macroangiopathy; treatment of hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis or myocardial ischemia.